Clinical Trial Update: Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated panitumumab in combination with paclitaxel as first-line therapy for head and neck cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Panitumumab (panitumumab)

Snippet

Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED